SCHEMBL8247645

SCHEMBL8247645

Cc1ccc(Nc2cc(N(C)C)nc(N3CCN(c4cccc[n+]4[O-])CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MAPT P10636 3/20 0.45
GALR2 O43603 7/20 0.41
GALR1 P47211 4/20 0.39
CCNE1 P24864 3/20 0.38
CDK2 P24941 3/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK1 P28482 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TP53 P04637 2/20 0.35
ROCK2 O75116 1/20 0.35
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GBA1 P04062 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244045 0.83 GALR2 (0.54) LMNAMAPTGALR2GALR1
SCHEMBL6352332 0.83 LMNA (0.41) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL3246394 0.81 MAPT (0.57) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL3244303 0.80 LMNA (0.49) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL8253195 0.79 MAPT (0.48) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL8254119 0.78 KDM4E (0.48) LMNAMAPTGALR2GALR1SMN1; SMN2
SCHEMBL8256643 0.78 MAPT (0.48) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL3242771 0.78 LMNA (0.49) LMNAMAPTGALR2GALR1CCNE1
SCHEMBL3262414 0.78 MAPT (0.50) LMNAMAPTGALR2GALR1CYP2C9
SCHEMBL6790642 0.78 LMNA (0.47) LMNAMAPTGALR2GALR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 LMNA 3975/4885MAPT 2638/4885GALR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.